Clinical Trials Logo

Alopecia Areata clinical trials

View clinical trials related to Alopecia Areata.

Filter by:

NCT ID: NCT05196711 Not yet recruiting - Alopecia Areata Clinical Trials

A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects

Start date: February 28, 2022
Phase: Phase 1
Study type: Interventional

This is a First-in-Human phase I study to evaluate the safety, tolerability and pharmacokinetic characteristics of MAX-40070 in Healthy SubjectThe study will be comprised of 2 parts; Part A and Part B. Part A will be conducted at NZCR, and Part B will be conducted at both NZCR and another site(s) in China (if required). Part A will include approximately 48 participants, and Part B will include approximately 30 participants.

NCT ID: NCT05177289 Recruiting - Clinical trials for Chemotherapy-induced Alopecia

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia

HairLight
Start date: February 28, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the prevention and management of chemotherapy-induced alopecia (CIA). Therefore, we hypothesize that PBMT can reduce the severity of CIA in gynecological and breast cancer patients, increasing the patient's QoL.

NCT ID: NCT05129800 Not yet recruiting - Clinical trials for Androgenetic Alopecia

Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study

Start date: December 2021
Phase:
Study type: Observational

This is a comparative retrospective study of the efficacy of platelet-rich plasma injections and injections with commercial products advertised to promote hair regrowth for patients with androgenetic alopecia.

NCT ID: NCT05129254 Withdrawn - Clinical trials for Androgenetic Alopecia

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The objective of this clinical study is to compare the safety and efficacy of a laser and topically applied platelet-rich plasma vs. platelet rich plasma injection in the treatment of male-pattern hair loss. Participating subjects will receive up to four (4) monthly treatments and will have a 12 month follow-up period.

NCT ID: NCT05098600 Completed - Clinical trials for Rheumatoid Arthritis

The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic

Start date: October 15, 2021
Phase:
Study type: Observational

The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a dermatology clinic of a metropolitan hospital.

NCT ID: NCT05084417 Enrolling by invitation - Psoriasis Clinical Trials

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

ClinPRO-DERM
Start date: June 9, 2023
Phase:
Study type: Observational [Patient Registry]

The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting. By regularly measuring outcomes longitudinally in patients treated in a real-world setting, this study will provide valuable and necessary information as to the impact of both the disease and its treatments on patients over time and will inform the optimal clinical management of patients with living with dermatological disease.

NCT ID: NCT05076006 Completed - Clinical trials for Cicatricial Alopecia

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Start date: May 19, 2021
Phase: Phase 2
Study type: Interventional

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The study team's research involves administrating patients a new investigational drug (a combined TYK/JAK inhibitor) which has been shown to be safe and well tolerated in clinical studies to date, and is being investigated in other conditions, such as AA. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

NCT ID: NCT05051761 Active, not recruiting - Alopecia Areata Clinical Trials

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

AA
Start date: September 4, 2021
Phase: Phase 3
Study type: Interventional

This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

NCT ID: NCT05041803 Active, not recruiting - Alopecia Areata Clinical Trials

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Start date: October 19, 2021
Phase: Phase 3
Study type: Interventional

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.

NCT ID: NCT05019066 Withdrawn - Hair Loss Clinical Trials

Oral Herbal Combination Formulation and Hair Growth in Women

Start date: September 30, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to test the effects of an herbal combination formulation on hair growth in women with self-perceived hair loss.The information from this study may help to better understand how certain herbal supplements can affect hair growth. This may lead to better understanding of the hair, hair loss and help develop naturally-based treatment regimens in the future.